Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in Non-BRCA Metastatic Breast Cancer With HRD
NCT03367689Phase 2Terminated
- Sponsor
- MEDSIR
- Start
- Apr 2018
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in breast cancer, sponsored by MEDSIR. Started Apr 2018; status: terminated.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03367689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03367689.